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A 61-year-old man was admitted to the intensive care unit for
hypotension and confusion. Hemodialysis was restarted 2
months before because of chronic allograft nephropathy,
after 24 years of kidney transplantation for IgA nephropathy.
At dialysis initiation, a discrete pericardial effusion was
noted. Despite daily dialysis, dry-weight reduction, and
reduced anticoagulation, effusion increased and slightly
impaired right ventricle function. Pericardocentesis was
delayed as colchicine 0.5mg daily rapidly allowed pain relief
and improvement of pericarditis; non-steroidal anti-inflam-
matory drugs were not associated because of active gastric
ulcers. Other long-term medications included cyclosporin
(100mg b.i.d., target trough level B60 ng/ml), prednisolone
(2mg o.d.), and rosuvastatin (10mg o.d.). As chest
pain recurred 12 days later, colchicine dose was increased
to 1mg o.d. After 7 days without any side effects, the patient
suddenly developed diarrhea, confusion, and hypotension.
Laboratory results are shown in Table 1. Multiple-organ
failure soon developed, with leucopenia, acute liver failure,
and rhabdomyolysis. Vasopressors, mechanical ventilation,
and continuous veno-venous hemofiltration were initiated.
Echocardiography showed a reduced pericardial effusion
and no cardiac dysfunction. Bacteriological and imaging
studies did not point to any infection. Mesenteric ischemia
was suspected, but exploratory laparotomy did not
show bowel necrosis. The patient died 36 h after admission
from refractory shock. Post-mortem examination was
performed.
What is your diagnosis?
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LDH (IU/l) 98–192 216 2521 7260
AST (IU/l) 6–33 33 1570 5330
ALT (IU/l) 14–63 14 464 1361
CK (IU/l) o200 47 705 798
Troponin I (ng/ml) o0.08 0.09 1.05 1.24
Lactate (mmol/l) o2.0 — 14.1 18.0
WBC (103/ml) 4.00–10.00 5.57 1.39 1.08
Neutrophils (103/ml) 1.60–7.00 3.40 0.83 0.65
Platelets (103/ml) 150–350 387 227 160
Reticulocytes (103/ml) 30–100 — 9 9
INR 0.8–1.3 1.06 2.08 3.52
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; CK, creatine kinase; ICU, intensive care unit;
INR, international normalized ratio; LDH, lactate dehydrogenase; WBC, white blood cells.
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The Diagnosis | Colchicine poisoning
Postmortem examination revealed numerous mitotic arrests
in the esophagus (Figure 1), small bowel, and bone marrow, a
characteristic feature of colchicine poisoning.
Colchicine has been used for treating gout and, more
recently, familial Mediterranean fever and pericarditis.1
Colchicine binds to tubulin and disrupts the microtubular
network, interfering with the cell-division process. This
mechanism accounts for both its anti-inflammatory proper-
ties and toxicity. Colchicine poisoning presents in three
successive stages: initial gastrointestinal symptoms (day 1),
followed by multiple-organ failure, associated with bone-
marrow suppression and myopathy (days 2–7), and poten-
tially complete recovery within a few weeks.2 The diagnosis is
difficult, because initial symptoms may suggest enterocolitis
or sepsis. Recognition of the toxidrome is the clue to the
diagnosis, as there is no established correlation between
plasmatic level and severity of illness. In fatal cases, post-
mortem examination of tissues with the highest turnover
rate—such as gastrointestinal tract and bone marrow—shows
numerous epithelial cell mitotic arrests, a characteristic
feature of colchicine toxicity.3
Physicians should be aware of the potential toxicity of
colchicine in chronic kidney disease (CKD) patients. Indeed,
gout is frequent in all stages of CKD, including transplant
recipients and dialysis patients. Furthermore, these patients
are often prescribed more than 10 medications—including
statins—to treat comorbid conditions, thus increasing the
risk of drug–drug reactions.
Although patients with renal and/or hepatic dysfunction
should be considered to be at high risk, colchicine can be well
tolerated by some,1 while others develop severe toxicity.
Indeed, the drug disposition has a marked interindividual
variability, with a narrow therapeutic-toxicity window. In
addition, many drug–drug interactions can increase colchi-
cine exposure.2 Colchicine elimination is mainly hepatic,
and, to a lesser extent, renal. CKD not only impairs renal
elimination of many drugs, but also reduces non-renal
clearance, leading to an increased bioavailability of drugs
predominantly metabolized by the liver.4 Mechanisms
accounting for this fact remain incompletely understood
and possibly involve the downregulation of various cyto-
chrome enzymes. Drug disposition results from P-glycopro-
tein 1, an efflux pump localized in the cell membrane in the
intestine, liver, kidney, and blood–brain barrier, and from the
intestinal and hepatic CYP3A4 isoform of cytochrome P450.
Drug-induced inhibition of these enzymes by macrolides,
calcium-channel blockers, calcineurin inhibitors, antifungal
agents, or statins can thus decrease colchicine metabolism
and increase the risk of colchicine toxicity.
Patients with renal failure and/or medications interfering
with colchicine metabolism, such as potent inhibitors of
P-glycoprotein 1 and CYP3A4 (cyclosporin in the present
case), are at very high risk of poisoning. Colchicine should
therefore be avoided, or only used with great caution, in this
population. Early recognition of severe colchicine toxidrome
should prompt immediate withdrawal of the drug and, if
available, considering the use of a specific experimental
treatment, Fab fragment antibodies.2
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Figure 1 |Post-mortem examination of the esophagus. Light microscopy reveals numerous epithelial cell mitotic arrests at different stages of
the cell-division process (arrows), a characteristic feature of colchicine toxicity (hematoxylin–eosin, scale bar¼ 10mm).
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